CLINICAL_TRIALS
trial_result
· 2017-06-06
Clinical Trial Update: High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms [Phase 3]
Summary
Phase 3 trial comparing high-dose oral ziprasidone to conventional dosing in participants with residual schizophrenia symptoms; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Donald C. Goff, MD | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2017-06-06